{
    "root": "2f263e62-338d-d420-e063-6294a90a77fc",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Clopidogrel",
    "value": "20250227",
    "ingredients": [
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYDROGENATED CASTOR OIL",
            "code": "ZF94AP8MEY"
        },
        {
            "name": "LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "2165RE0K14"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "CLOPIDOGREL BISULFATE",
            "code": "08I79HTP27"
        }
    ],
    "indications": "clopidogrel tablets p2y 12 platelet inhibitor indicated : acute coronary syndrome – patients non–st-segment elevation acs ( unstable angina [ ua ] /non–st-elevation myocardial infarction [ nstemi ] ) , clopidogrel tablets shown reduce rate myocardial infarction ( myocardial infarction ) stroke . ( 1.1 ) – patients st-elevation myocardial infarction ( stemi ) , clopidogrel tablets shown reduce rate myocardial infarction stroke . ( 1.1 ) recent myocardial infarction , recent stroke , established peripheral arterial disease . clopidogrel tablets shown reduce rate myocardial infarction stroke . ( 1.2 )",
    "contraindications": "acute coronary syndrome ( 2.1 ) – initiate clopidogrel tablets single 300 mg oral loading dose continue 75 mg daily . – initiating clopidogrel tablets without loading dose delay establishment antiplatelet effect several days . recent myocardial infarction , recent stroke , established peripheral arterial disease : 75 mg daily orally without loading dose . ( 2.2 )",
    "warningsAndPrecautions": "clopidogrel tablets usp , 75 mg pink colored , round , biconvex , beveled edge , film-coated tablets debossed ‘ e ’ one side ‘ 34 ’ side . ndc : 70518-1898-00 ndc : 70518-1898-01 ndc : 70518-1898-02 packaging : 30 1 blister pack packaging : 30 1 blister pack packaging : 90 1 bottle plastic store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . protect moisture . preserve well-closed containers . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "active pathological bleeding , peptic ulcer intracranial hemorrhage ( 4.1 ) hypersensitivity clopidogrel component product ( 4.2 )",
    "indications_original": "Clopidogrel tablets are a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome –   For patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets have been shown to reduce the rate of  myocardial infarction (MI) and stroke. (1.1) –   For patients with ST-elevation myocardial infarction (STEMI), clopidogrel tablets have been shown to reduce the rate of MI and stroke. (1.1) Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel tablets have been shown to reduce the rate of MI and stroke. (1.2)",
    "contraindications_original": "Acute coronary syndrome ( 2.1 ) –    Initiate clopidogrel tablets with a single 300 mg oral loading dose and then continue at 75 mg once daily. –     Initiating clopidogrel tablets without a loading dose will delay establishment of an antiplatelet effect by several days. Recent MI, recent stroke, or established peripheral arterial disease: 75 mg once daily orally without a loading dose. ( 2.2 )",
    "warningsAndPrecautions_original": "Clopidogrel Tablets USP, 75 mg are pink colored, round, biconvex, beveled edge, film-coated tablets debossed with ‘E’ on one side and ‘34’ on the other side.\n                  NDC: 70518-1898-00\n                  NDC: 70518-1898-01\n                  NDC: 70518-1898-02\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from moisture.\n                  \n                  Preserve in well-closed containers.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage (4.1) Hypersensitivity to clopidogrel or any component of the product (4.2)"
}